MEMPHIS, TN – [Date] – In a landmark study that promises to redefine long-term care for childhood cancer survivors, scientists at St. Jude Children’s Research Hospital have unveiled compelling evidence that a survivor’s genetic makeup plays a far more significant role in the risk of developing secondary cancers than previously understood. This groundbreaking research, published today in The Lancet Oncology, quantifies for the first time the precise contributions of genetic predisposition, along with life-saving cancer treatments, to the likelihood of secondary malignancies—a leading cause of mortality for this vulnerable population.
The findings challenge conventional wisdom, suggesting that genetics can be as, or even more, influential than chemotherapy exposures in determining subsequent cancer risk for certain types of secondary cancers. This critical insight, derived from the unparalleled data of the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS)—two of the world’s most comprehensive childhood cancer survivor cohorts—marks a pivotal moment in understanding and mitigating the long-term health challenges faced by these individuals.
Unveiling the Complex Tapestry of Risk
The Silent Threat: Secondary Cancers
The triumph of modern medicine has dramatically improved survival rates for children diagnosed with cancer. Decades ago, a childhood cancer diagnosis was often a death sentence; today, over 80% of children with cancer survive into adulthood. This success, however, has brought into sharper focus a new set of challenges: the late effects of cancer and its intensive treatments. Among these, the development of a secondary cancer—a new, unrelated malignancy that arises years or even decades after the primary cancer treatment—stands as one of the most devastating. Secondary cancers not only represent a significant blow to the quality of life for survivors but have also emerged as the primary cause of mortality in long-term survivors, surpassing even recurrence of the original cancer.
For years, clinical focus has predominantly been on the adverse effects of radiation and chemotherapy, the very treatments that saved these young lives. While their efficacy in eradicating primary cancers is undeniable, the long-term collateral damage to healthy tissues, including DNA mutations that can lead to new cancers, has been a well-documented concern. However, the precise extent to which different factors—treatment exposures, genetic predispositions, and even lifestyle choices—contribute to this risk at a population level remained largely unquantified. This knowledge gap has hindered the development of truly personalized and proactive surveillance strategies for survivors.
A Legacy of Research: St. Jude’s Pioneering Cohorts
The St. Jude Children’s Research Hospital stands at the forefront of this critical research, thanks to its unique commitment to not only treating but also understanding the long-term outcomes of childhood cancer. The institution houses two of the most extensive and invaluable resources for childhood cancer survivorship studies globally: the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS).
The St. Jude LIFE study meticulously follows survivors treated at St. Jude, gathering comprehensive data on their health outcomes, treatment histories, genetic profiles, and lifestyle factors over many years. Similarly, the CCSS, a multi-institutional consortium also headquartered at St. Jude, compiles detailed information from thousands of childhood cancer survivors across North America. Together, these cohorts represent an unparalleled wealth of information, encompassing over 10,000 survivors, with more than 12,000 individuals having undergone extensive genetic sequencing. This vast, longitudinal dataset provides an extraordinary opportunity to dissect the intricate interplay of factors contributing to long-term health outcomes, including the development of secondary cancers. Without the foresight and sustained investment in these massive, long-term studies, the kind of nuanced analysis presented in this new research would simply not be possible.
The Evolution of Understanding: From Association to Attribution
Prior research had established associations between particular treatment exposures, certain genetic predispositions, and various lifestyle factors with an increased risk of secondary cancers. For instance, it was known that high-dose radiation to the chest could increase the risk of breast cancer later in life, and certain genetic mutations predisposed individuals to specific cancer types. However, what remained elusive was the relative contribution of each of these factors to the overall risk at a population level. Clinicians and researchers could identify risk factors, but they lacked a comprehensive picture of their proportional impact.
"We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition," stated Dr. Yadav Sapkota, corresponding author of the study and a faculty member in the St. Jude Department of Epidemiology and Cancer Control. "We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level." This distinction—moving from mere association to precise attribution—is a critical leap forward, enabling a more informed and targeted approach to survivorship care.
Quantifying the Contributors: A Deep Dive into Data
Methodology: A Comprehensive Approach
To bridge this critical knowledge gap, the St. Jude scientists embarked on an ambitious comparative analysis. They meticulously examined data from over 10,000 survivors drawn from both the St. Jude LIFE and CCSS cohorts, collectively representing the largest survivor cohort in North America. This extensive dataset was a treasure trove of information, including detailed records of primary cancer diagnoses and treatments, specific radiation and chemotherapy exposures, comprehensive genetic information (including both common and rare variants), lifestyle factors such as diet and exercise, and, crucially, the presence or absence of a secondary cancer.
The researchers employed sophisticated statistical models to disentangle and quantify the individual and combined contributions of these diverse factors to the occurrence of secondary cancers. This rigorous methodology allowed them to move beyond simple correlations and assign a percentage of risk attribution to each category of influence. Dr. Greg Armstrong, co-author and chair of the St. Jude Department of Epidemiology and Cancer Control, underscored the unique capabilities of these studies, noting, "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing." This unparalleled access to both clinical and genetic data on such a large scale was instrumental in yielding these groundbreaking results.
The Dominance of Radiation Exposure
The study confirmed what has long been suspected: radiation exposure during primary cancer treatment remains the most significant contributor to secondary cancer risk. The analysis attributed approximately 40% or more of the overall risk to prior radiation therapy. Historically, radiation therapy was a cornerstone of many childhood cancer treatments, particularly for solid tumors and certain leukemias, due to its potent ability to destroy rapidly dividing cancer cells. However, its indiscriminate nature means that healthy cells in the irradiated field also sustain damage, increasing the risk of malignant transformation years later.
The findings of this study provide further empirical support for the ongoing paradigm shift in modern pediatric oncology. Recognizing the long-term adverse effects of radiation, contemporary treatment protocols have already moved towards significantly lowered radiation doses, more precisely targeted radiation fields (such as proton therapy), or even the complete elimination of radiation in favor of more effective alternative therapies when possible. This research reinforces the importance of these efforts, validating the clinical decisions to minimize radiation exposure while maintaining curative potential. Understanding this high attribution percentage underscores the necessity of continued innovation in radiation delivery and the exploration of non-radiogenic treatment modalities.
Genetics: An Unsung Player Takes Center Stage
Perhaps the most surprising and impactful finding of the study was the revelation regarding the substantial contribution of genetic predisposition to secondary cancer risk. While the late effects of chemotherapy have been extensively studied, the role of inherited genetic factors in survivors’ susceptibility to new cancers has been less clearly defined and, crucially, less quantified at a population level.
The St. Jude researchers delved deep into the genetic profiles of the survivors, examining hundreds of common genetic variants previously linked to cancer development in the general population. These variants were integrated into what is known as a polygenic risk score (PRS), a statistical measure that estimates an individual’s cumulative genetic susceptibility to a particular disease based on multiple genetic markers. They also investigated the impact of certain rare genetic variants. The analysis revealed that, depending on the specific type of secondary cancer, the polygenic risk score contributed a significant 5% to 37% of the overall risk.
This finding challenges the "conventional wisdom" within the field, as Dr. Sapkota noted: "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field." This means that for certain secondary malignancies, an individual’s inherited genetic predisposition might be a stronger predictor of risk than the specific chemotherapy agents they received.
Dr. Yutaka Yasui, another co-author from the St. Jude Department of Epidemiology and Cancer Control, commented on the broader implications of polygenic risk scores: "Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population." However, he added a crucial caveat regarding this specific population: "Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures." This suggests that while PRS might not yet be universally precise enough for general population screening, their utility for a highly specific, at-risk population like childhood cancer survivors could be transformative.
Chemotherapy’s Variable Impact
The study also provided a more nuanced understanding of chemotherapy’s contribution to secondary cancer risk. The analysis indicated that chemotherapy contributed between 8% and 35% of subsequent cancer risk, with the variation depending on the specific type of secondary cancer. While the potential for certain chemotherapeutic agents to induce secondary malignancies (e.g., alkylating agents and topoisomerase inhibitors linked to secondary leukemias) has been well-documented, quantifying its proportional contribution alongside other factors offers a clearer picture.
The wide range of attribution for chemotherapy likely reflects the diversity of agents used in pediatric oncology, their varying mechanisms of action, cumulative doses, and interactions with individual genetic susceptibilities. This finding underscores the complexity of treatment-related risks and highlights the need for continued research into developing less genotoxic chemotherapy agents that maintain high efficacy.
Lifestyle Factors: A Nuanced Perspective
In contrast to radiation, genetics, and chemotherapy, lifestyle factors such as diet and exercise appeared to contribute much less to the risk of secondary cancers in this study, accounting for only 1% to 6% of the risk. This finding might seem counterintuitive, given the well-established role of healthy lifestyle choices in general cancer prevention.
However, the researchers provided an important clarification: the majority of survivors in this study were relatively young, primarily in their 20s and 30s. At these younger ages, the cumulative effects of lifestyle choices on cancer development may not yet have had sufficient time to manifest. Many cancers, including secondary cancers, are diseases that often take decades to develop.
Dr. Sapkota emphasized that this finding should not diminish the importance of healthy living for survivors: "We know healthy lifestyle choices are important for survivors. In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac wellbeing, so it is still important for clinicians to encourage—and patients to seek—a healthy lifestyle." This underscores that while lifestyle’s direct impact on secondary cancer risk may be limited at younger ages, its overall benefits for long-term health and well-being in survivors remain crucial.
Official Responses and Expert Commentary
The researchers involved in this pivotal study expressed both the significance of their findings and the potential for their immediate translation into clinical practice. Their collective responses highlight a paradigm shift in how survivorship care should be approached.
A Paradigm Shift in Survivorship Care
Dr. Sapkota articulated the profound shift in understanding necessitated by the study’s results: "Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk. Our study suggests that we need to better account for genetic predisposition in this population." This statement represents a direct challenge to the status quo, advocating for a more holistic assessment of risk that integrates inherited susceptibility alongside treatment history. The implications for clinical guidelines and personalized risk stratification are immense. It moves the conversation beyond simply documenting past exposures to actively profiling an individual’s inherent biological vulnerability.
The Power of Cohort Studies
The ability to make such precise attributions is a testament to the monumental effort invested in studies like St. Jude LIFE and CCSS. Dr. Armstrong’s comment, "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing," underscores the irreplaceable value of these long-term, meticulously curated databases. These cohorts are not merely collections of patient records; they are living laboratories that allow researchers to track health trajectories over decades, correlating complex variables with concrete outcomes. The continuous funding and dedication required to maintain such studies are a critical investment in the future health of cancer survivors.
Towards Personalized Medicine for Survivors
Dr. Yasui’s insights into the clinical utility of polygenic risk scores further elaborate on the potential for personalized medicine in this context. While acknowledging the general limitations of PRS for broad clinical application in the general population, he highlighted their specific promise for childhood cancer survivors. This distinction is crucial: in a population already identified as high-risk due to their treatment history, adding genetic risk stratification can significantly refine personalized risk assessments. This could pave the way for a future where genetic data, combined with treatment histories, informs highly tailored surveillance plans.
Redefining the Future of Survivorship Care
The findings from St. Jude are not merely academic; they carry profound implications for the clinical management, psychological support, and long-term well-being of childhood cancer survivors. By quantifying the contributions of various risk factors, this study empowers clinicians and survivors alike with unprecedented clarity.
Precision Screening and Early Detection
One of the most immediate and impactful implications is the potential for highly personalized and precise cancer screening protocols. Survivors identified with a strong genetic predisposition to specific secondary cancers, in addition to their treatment-related risks, could receive more regular, intensive, and targeted screenings. For example, a survivor with a high genetic risk for breast cancer who also received chest radiation might warrant earlier and more frequent mammograms or MRIs than a survivor with similar radiation exposure but a low genetic risk. This proactive approach aims to catch secondary cancers at their earliest, most treatable stages, significantly improving prognosis and survival. Specialized survivorship clinics, in conjunction with primary care physicians and oncologists, will be instrumental in implementing such nuanced screening strategies.
Empowering Survivors Through Knowledge
Knowledge is power, and this research provides survivors with a deeper understanding of their individual risk profile. Armed with the information about their unique combination of treatment-related, genetic, and lifestyle risk factors, survivors can become more active participants in their own healthcare. They can better advocate to their health care providers about the need for specific screenings, engage in more informed discussions about their long-term health, and make personalized decisions about their lifestyle. Genetic counseling will likely become an even more integral component of survivorship care, helping individuals understand their genetic test results and their implications for future health.
Tailoring Prevention Strategies
While the study highlights the historical impact of radiation, which is already being mitigated in modern protocols, the increased understanding of genetic predisposition opens new avenues for prevention. Future research could explore gene-environment interactions, identifying specific genetic variants that make individuals more susceptible to certain chemotherapies, potentially guiding treatment choices to minimize long-term risks. The ultimate goal is to move beyond simply managing late effects to actively preventing them whenever possible, or at least mitigating their severity through highly targeted interventions.
Policy and Research Directives
This study is likely to influence the development of updated clinical guidelines for survivorship care, urging greater integration of genetic risk assessment into routine follow-up. It also points to critical directions for future research. This includes validating polygenic risk scores in more diverse survivor populations, further elucidating the complex interplay between specific genetic variants and particular treatment exposures, and ultimately, developing targeted pharmacologic or lifestyle interventions based on individual genetic profiles to reduce secondary cancer risk.
A Renewed Hope: Extending and Enhancing Lives
Dr. Sapkota’s concluding remarks encapsulate the overarching mission of this research: "Second cancers remain the leading cause of mortality for childhood cancer survivors. Now that we have quantified the contributions of treatment, genetics and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect and treat these cancers, and hopefully extend these survivors’ lives." This study offers not just a deeper scientific understanding, but a renewed sense of hope for the thousands of individuals who have triumphed over childhood cancer, promising them a future where their health can be more precisely safeguarded and their lives extended and enriched.
Authors and Funding
The study’s first author is Achal Neupane, of St. Jude. The study’s other authors include Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison, and Yutaka Yasui, all from St. Jude; Qi Liu from the University of Alberta; Cindy Im, Lucie Turcotte, and Joseph Neglia from the University of Minnesota; Monica Gramatges from Baylor College of Medicine; Rebecca Howell from the University of Texas MD Anderson Cancer Center; and Smita Bhatia from the University of Alabama at Birmingham.
The study was supported by grants from the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547, and CA21765) and ALSAC, the fundraising and awareness organization of St. Jude.
About the Author
